Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR) "CLEAR-FDR"


Phase 2 Results

Summary of Purpose

The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a full dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 16 December 2015.

1 Sep 2013 18 Oct 2013 1 Jan 2015 1 Apr 2015 1 Oct 2015 23 Oct 2015
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment